Two Sigma Investments LP Trims Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Two Sigma Investments LP trimmed its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 43.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 606,208 shares of the biopharmaceutical company’s stock after selling 456,652 shares during the quarter. Two Sigma Investments LP owned approximately 0.39% of TG Therapeutics worth $18,247,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in TG Therapeutics by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company’s stock valued at $469,454,000 after buying an additional 209,190 shares during the period. Clearbridge Investments LLC purchased a new stake in shares of TG Therapeutics in the 4th quarter valued at about $55,237,000. Northern Trust Corp boosted its position in shares of TG Therapeutics by 8.6% during the 4th quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company’s stock valued at $46,141,000 after acquiring an additional 120,785 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of TG Therapeutics by 7.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company’s stock worth $38,212,000 after purchasing an additional 84,904 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in shares of TG Therapeutics by 1.2% during the fourth quarter. Invesco Ltd. now owns 929,743 shares of the biopharmaceutical company’s stock worth $27,985,000 after purchasing an additional 10,989 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Stock Performance

NASDAQ:TGTX opened at $34.24 on Friday. The company has a market capitalization of $5.44 billion, a price-to-earnings ratio of -342.37 and a beta of 2.21. The business has a 50 day moving average of $38.24 and a 200 day moving average of $34.16. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. TG Therapeutics, Inc. has a 1-year low of $15.16 and a 1-year high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business had revenue of $120.86 million for the quarter, compared to analysts’ expectations of $117.07 million. During the same period last year, the business posted ($0.07) earnings per share. The company’s revenue was up 90.4% compared to the same quarter last year. On average, sell-side analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on TGTX shares. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a research note on Tuesday, March 4th. Wall Street Zen upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $40.80.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.